Lanadelumab for Treatment of COVID-19 Disease (COVID_LAN)
Sponsor: Radboud University Medical Center
Listed as NCT04422509, this PHASE1/PHASE2 trial focuses on COVID-19 and remains completed. Sponsored by Radboud University Medical Center, it has been updated 9 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Sep 2021 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Radboud University Medical Center
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .